1. Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes
- Author
-
Guillermo Quintás, Jos Kleinjans, Eugenia Pareja Ibars, Teresa Martínez-Sena, Isabel Conde, and José V Castell
- Subjects
0301 basic medicine ,Male ,Drug-induced liver injury ,Health, Toxicology and Mutagenesis ,Disease ,Toxicology ,Bioinformatics ,Toxicogenomics and Omics Technologies ,Severity of Illness Index ,Medicine ,Longitudinal Studies ,Child ,media_common ,Liver injury ,Aged, 80 and over ,Cholestasis ,Alanine Transaminase ,General Medicine ,Middle Aged ,Phenotype ,Drug development ,Disease Progression ,Alkaline phosphatase ,DILI ,Female ,Chemical and Drug Induced Liver Injury ,Drug ,Adult ,Adolescent ,media_common.quotation_subject ,Glycerophospholipids ,Bile Acids and Salts ,03 medical and health sciences ,Young Adult ,Metabolomics ,Humans ,Clinical significance ,Aged ,030102 biochemistry & molecular biology ,business.industry ,Hepatotoxicity ,medicine.disease ,Alkaline Phosphatase ,030104 developmental biology ,Drug liver toxicity ,business ,Biomarkers - Abstract
Drug-induced liver injury (DILI) is an adverse toxic hepatic clinical reaction associated to the administration of a drug that can occur both at early clinical stages of drug development, as well after normal clinical usage of approved drugs. Because of its unpredictability and clinical relevance, it is of medical concern. Three DILI phenotypes (hepatocellular, cholestatic, and mixed) are currently recognized, based on serum alanine aminotransferase (ALT) and alkaline phosphatase (ALP) values. However, this classification lacks accuracy to distinguish among the many intermediate mixed types, or even to estimate the magnitude and progression of the injury. It was found desirable to have additional elements for better evaluation criteria of DILI. With this aim, we have examined the serum metabolomic changes occurring in 79 DILI patients recruited and monitored using established clinical criteria, along the course of the disease and until recovery. Results revealed that free and conjugated bile acids, and glycerophospholipids were among the most relevant metabolite classes for DILI phenotype characterization. Using an ensemble of PLS–DA models, metabolomic information was integrated into a ternary diagram to display the disease phenotype, the severity of the liver damage, and its progression. The modeling implemented and the use of such compiled information in an easily understandable and visual manner facilitates a straightforward DILI phenotyping and allow to monitor its progression and recovery prediction, usefully complementing the concise information drawn out by the ALT and ALP classification. Supplementary Information The online version contains supplementary material available at 10.1007/s00204-021-03114-z.
- Published
- 2021